[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bioteck S.p.A.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100645290",false,"NCT07680491","Non-surgical Treatment of Peri-implant Pockets With H42","H42","Inclusion Criteria:\n\n* Men or women with age ≥ 25 and ≤ 65 years.\n* Subjects affected by peri-implant pockets with probing depth (PD) in the range between 6 to 8 mm.\n* Each subject can have from 1 to 5 defects.\n* Subjects willing to provide signed informed consent to clinical investigation participation.\n\nExclusion Criteria:\n\n* Use of aspirin and antiplatelet agents a week before treatment.\n* Subjects smokers ≥ 10 cigarettes per day.\n* Subjects presenting current or previous bleeding disorders.\n* Subjects taking or having indications for anticoagulant therapy.\n* Concomitant treatments or procedures to improve gum health over the last six months before the clinical investigation enrolment, such as HA gel treatments, injection of fillers, and surgery.\n* Subjects suffering from infectious diseases, including herpes simplex infection, active hepatitis, or human immunodeficiency virus.\n* Subjects with dental aesthetic surgery in the preceding 12 months before the clinical investigation enrolment.","ALL","25 Years","65 Years",{"count":19,"type":20},56,"ESTIMATED","OBSERVATIONAL","This prospective, observational study evaluates the efficacy and safety of H42 non-surgical treatment for peri-implant pockets. The trial involves 56 patients, with 28 subjects receiving the H42 treatment and 28 acting as a control group to monitor soft tissue healing and bone level changes.\n\nClinical outcomes focus on Pocket Probing Depth (PPD) and Silness and Löe Plaque Index (PI) measured at baseline, 1 month, and 3 months. Gingival inflammation, pain intensity on a 0-10 NRS scale, and absence of infection are monitored at baseline, 7, 14, and 21 days, and at 1 and 3 months. Additionally, a five-point tissue assessment evaluates color, suppuration, granulation tissue, bleeding, and incision margins. Radiographic analysis at baseline and 3 months uses standardized periapical x-rays to measure bone level, intra-bony defect height, width, and angulation. Safety is assessed through the continuous registration of adverse events.",[24],"Peri-implantitis",[13],"RECRUITING","2026-07-01",{"date":29,"type":30},"2026-07-02","ACTUAL",{"date":32,"type":30},"2025-12-03",{"date":34,"type":20},"2027-09-30",{"name":36,"class":37},"Bioteck S.p.A.","INDUSTRY",""]